Article Sidebar

PDF (Tiếng Việt)
Published: 2023-01-30
Abstract Views: 207
Views PDF (Tiếng Việt): 354
DOI: https://doi.org/10.52852/tcncyh.v160i12V2.1378
Issue
Vol. 160 No. 12V2 (2022)
Section
Các bài báo
How to Cite
Hương, C. L. ., & Dung, K. T. K. . (2023). 27. The efficacy of surfactant replacement therapy on respiratory distress syndrome due to neonatal pneumonia. Journal of Medical Research, 160(12V2), 227-235. https://doi.org/10.52852/tcncyh.v160i12V2.1378

27. The efficacy of surfactant replacement therapy on respiratory distress syndrome due to neonatal pneumonia

Chu Lan Huong, Khu Thi Khanh Dung

Main Article Content

Abstract

Neonatal pneumonia is a common cause of respiratory distress syndrome in term and near term infants. Plasma protein and cytokines in inflamatory fluid can cause inactivation of surfactant, leading to poor gas exchange and respiratory failure. This study aimed to investigate the efficacy of surfactant replacement therapy in treatment of respiratory distress syndrome due to neonatal pneumonia. 97 neonates with severe respiratory distress syndrome due to pnemonia were recruited in this study. The selected neonates were treated with Poractant alpha 100 mg/kg, given via endotrachea tube. The patients were observed for the change in oxygen requirement and oxygenation before and after surfactant administration 1-hour, 8-hour, 12-hour, 24-hour, 48-hour and 72-hour. The mean gestaional age and mean birth weight were 36.8 ± 2.6 weeks and 2988 ± 565gram. There was an increase in SpO2, PaO2 with the mean of SpO2, PaO2 before surfactant were 83.6 ± 15.1%, 41.8 ± 28.4mmHg and 94.0 ± 9.0%, 96.7 ± 56.4mmHg after surfactant 72 hours. There was a decrease in FiO2 from 92.6% before to 57.7% after surfactant, OI from 42.2 before to 12.3 after surfactant and AaDO2 from 559.9 to 285.5 after surfactant administration (p < 0.05). Conclusion: In neonates with severe pneumonia, surfactant replacement therapy may improve lung functions and reduce oxygen requirement.

Article Details

Keywords

neonatal pneumonia, respiratory distress syndrome, surfactant replacement therapy

References

1. Robert Resnik. Fetal Lung Development and Surfactant. In: Kendig’s Disorders of the Respiratory Tract in Children. Ninth edition. Elsevier; 2019.
2. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet Lond Engl. 1980;1(8159):55-59. doi: 10.1016/s0140-6736(80)90489-4.
3. Jeon GW. Surfactant preparations for preterm infants with respiratory distress syndrome: Past, present, and future. Korean J Pediatr. 2019;62(5):155-161. doi: 10.3345/kjp.2018.07185.
4. Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008;121(2):419-432. doi:10.1542/peds.2007-3283.
5. Flidel-Rimon O, Shinwell ES. Respiratory Distress in the Term and Near-term Infant. NeoReviews. 2005;6(6):e289-e297. doi: 10.1542/neo.6-6-e289.
6. Tan K, Lai NM, Sharma A. Surfactant for bacterial pneumonia in late preterm and term infants. Cochrane Database Syst Rev. 2012;(2). doi: 10.1002/14651858.CD008155.pub2.
7. Reuter S, Moser C, Baack M. Respiratory Distress in the Newborn. Pediatr Rev. 2014;35(10):417-429.
8. American Academy of Pediatrics. Reference Range Values for Pediatric Care. Second edition. American Academy of Pediatrics Publishing Staff; 2019. doi: 10.1542/9781610022811.
9. Esan Ayodele Jacob. Hematological differences in newborn and aging: a review study. Hematol Transfus Int J. 2016;3(3):178-190. doi: 10.15406/htij.2016.03.00067.
10. Deshpande S, Suryawanshi P, Ahya K, Maheshwari R, Gupta S. Surfactant Therapy for Early Onset Pneumonia in Late Preterm and Term Neonates Needing Mechanical Ventilation. J Clin Diagn Res JCDR. 2017;11(8):SC09-SC12. doi: 10.7860/JCDR/2017/28523.10520.
11. Lotze A, Whitsett JA, Kammerman LA, Ritter M, Taylor GA, Short BL. Surfactant protein A concentrations in tracheal aspirate fluid from infants requiring extracorporeal membrane oxygenation. J Pediatr. 1990;116(3):435.
12. Lưu Thị Hồng Quyên, Nguyễn Thị Quỳnh Nga. Đặc điểm dịch tễ học lâm sàng và giá trị của PCR đa mồi trong chẩn đoán viêm màng não nhiễm khuẩn ở trẻ sơ sinh. Luận văn bác sĩ chuyên khoa cấp II. Trường Đại học Y Hà Nội; 2020.
13. Herting E, Gefeller O, Land M, van Sonderen L, Harms K, Robertson B. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics. 2000;106(5):957-964; discussion 1135. doi: 10.1542/peds.106.5.957.
14. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr. 1998;132(1):40-47. doi: 10.1016/s0022-3476(98)70482-2.
15. Rong Z, Mo L, Pan R, et al. Bovine surfactant in the treatment of pneumonia-induced–neonatal acute respiratory distress syndrome (NARDS) in neonates beyond 34 weeks of gestation: A multicentre, randomized, assessor-blinded, placebo-controlled trial. Eur J Pediatr. 2021;180(4):1107-1115. doi: 10.1007/s00431-020-03821-2.
16. Ng EH, Shah V. Guidelines for surfactant replacement therapy in neonates. Paediatr Child Health. 2021;26(1):35-41. doi: 10.1093/pch/pxaa116.